Baxter CEO Almeida to retire, Kidney Care business becomes standalone company
In January 2023, Baxter announced plans to spin its renal care and acute therapies units into an independent, publicly traded company. It said at the time that it expected the company to stand alone in the next 12 to 18 months. In July of last year, Baxter picked “Vantive” as the name of the proposed business.